The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study

David Kotzerke(University Hospital Leipzig), Maren Knödler(Humboldt-Universität zu Berlin), F. Moritz, Peter Hambsch(Leipzig University), Florian Lordick(Leipzig University), Dirk Forstmeyer(University Hospital Leipzig), Thomas Kuhnt(Leipzig University), Maryam Yahiaoui‐Doktor(Leipzig University), Luisa Mantovani(Heidelberg University), Kathrin Hering(University Hospital Leipzig)
Journal of Geriatric Oncology
May 10, 2019
10.1016/j.jgo.2019.04.004
Cited by 32

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|1.1k